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NK cells are CD3(−)CD19(−) large granular 
lymphocytes that can kill infected or malig-
nantly transformed cells and produce cytokines, 
such as IFN-γ, that regulate the innate and 
adaptive immune systems. Similar to other 
lymphocytes, human NK cells are thought to 
originate from CD34(+) hematopoietic pro-
genitor cells (HPCs) that diff  erentiate through 
discrete stages of maturation (1). Whereas T and 
B cell developmental intermediates have been 
identifi  ed within the human thymus and BM, 
respectively, in vivo stages of human NK cell 
diff  erentiation have not been defi  ned.
Our current understanding of NK cell de-
velopment stems primarily from fi  ndings in 
mice and in vitro diff  erentiation systems (1, 2). 
Early studies revealed that IL-15 can promote 
the diff  erentiation of cytolytic NK cells from 
CD34(+) HPCs in vitro (3). IL-15 signals in 
part via the IL-2 receptor β chain (CD122), 
and mice lacking either IL-15 or CD122 have 
severe NK cell defi   ciencies supporting their 
physiological roles during NK cell develop-
ment in vivo (4, 5). Other cytokines, such as 
fl  t3 ligand (FL) and c-kit ligand (KL), can in-
duce the generation of CD122(+) NK cell 
precursors (NKPs) from IL-15–nonresponsive 
mouse BM progenitors, indicating that the 
  acquisition of “IL-15 responsiveness” marks a 
critical stage in mouse NK cell development 
(6), and indeed the earliest committed mouse 
NKPs in vivo express CD122 yet lack other 
markers of mature NK cells (7). CD122 ex-
pression is also maintained throughout the 
downstream stages of mouse NK cell diff  eren-
tiation, which were recently elucidated by cor-
relating integrin expression patterns with stages 
of proliferation, receptor expression, and ac-
quisition of NK cell function (8).
In humans, CD122 expression on freshly 
isolated CD34(+) HPCs is below the limits of 
detection by fl  ow cytometry, making it diffi   -
cult to identify IL-15–responsive NKPs (9–11). 
In addition, mouse NK cells express NK1.1 
and DX5, whereas human NK cells are gener-
ally defi  ned by the expression of CD56, which 
is not expressed by mouse NK cells (1, 2). 
Therefore, it has remained a challenge to iden-
tify the orthologous NK cell developmental 
intermediates in humans. However, despite 
these diff  erences in antigen expression between 
the species, results from in vitro diff  erentiation 
assays initiated with human CD34(+) HPCs 
have revealed important general consistencies 
with the in vivo mouse data. Both the human 
in vitro data as well as the mouse in vivo data 
indicate that NK cell functional maturity (i.e., 
the ability to mediate natural cytotoxicity and 
produce IFN-γ) is acquired at a late stage of 
development, likely distal to the acquisition of 
surface CD56 in humans (8, 12, 13). In addi-
tion, similar to mouse NK cell diff  erentiation, 
in vitro human NK cell diff  erentiation is asso-
ciated with the nonrandom, orderly acquisition 
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of NK cell receptors (1, 2), with CD161 and NKp46 being 
among the fi  rst NK cell receptors to be detected, followed by 
CD94, and lastly CD16 and killer-cell immunoglobulin-like 
receptors (KIRs; references 3, 12, 14). Collectively, these re-
sults suggest that human NK cells would diff  erentiate through 
discrete developmental stages in vivo; however, the precise 
intermediates have not yet been described.
Another major diff  erence between mice and humans is 
that the latter have two NK cell subsets, with the CD56bright 
subset being substantially more capable of proliferation and 
cytokine production, whereas the fresh CD56dim subset dis-
plays a higher capacity for natural cytotoxicity ex vivo (15). 
Currently, the developmental relationship between mature 
human NK cell subsets is unknown as are their sites of dif-
ferentiation in vivo (1, 15). Although ≥90% of periph-
eral blood (PB) NK cells are CD56dimCD16(+)KIR(+), 
the majority of NK cells in human LNs and tonsils are 
CD56brightCD16(−)KIR(−) (16, 17). We recently de-
scribed a population of CD34dimCD45RA(+) HPCs that 
is highly enriched with NKPs and that is unique among all 
CD34(+) subsets by its ability to colocalize within the T 
cell–rich regions of human LNs near mature CD56bright NK 
cells (9). Based on these fi  ndings, we hypothesized that sec-
ondary lymphoid tissues (SLT) might be sites of CD56bright 
NK cell diff  erentiation and would, therefore, contain all the 
requisite NK cell developmental intermediates spanning the 
continuum of diff  erentiation from a CD34(+) progenitor 
to a CD56bright NK cell. In the current study, we identify 
and functionally characterize such intermediates from SLT, 
thereby providing a new model for the development of hu-
man NK cells in vivo.
RESULTS
Delineation of NK cell developmental stages 
within human SLT
We noted from previous work that although primary 
  CD56bright NK cells found in BM and PB coexpress CD94, 
the majority of CD56bright NK cells derived in vitro from 
CD34(+) HPCs cultured in IL-15 lack CD94 (Fig. 1 A; ref-
erence 9), suggesting that a CD94(−) intermediate stage 
may exist in vivo. Interestingly, fresh human SLT contain 
CD3(−)CD56(+)CD94(−) cells (Fig. 1 A). We speculated 
that the latter may be immature NK cell developmental in-
termediates, and additional phenotypic analyses revealed that 
these cells are uniformly CD117(+) and some express CD34 
(Fig. 1 B). Based on these results, we made the following 
three predictions of in vivo human NK cell development. 
First, given that CD34 and CD94 are mutually exclusive 
  antigens (Fig. 1 B, right), a developing NK cell would fi  rst 
lose CD34 before acquiring CD94. Second, as all CD3(−)-
CD56(+) cells in SLT express at least either CD117 and/or 
CD94 (Fig. 1 B, left), NK cell developmental intermediates 
with the CD34(−)CD94(−) phenotype would be identifi  -
able by the expression of CD117. Third, the CD34(+) HPC, 
which represents the human IL-15–responsive NKP, would 
express CD117.
Within human SLT, CD117 expression on CD34dim
CD45RA(+) HPCs identifi   es a CD56(+) and CD56(−) 
population (Fig. 1 C). The gradual up-regulation of CD56 
expression seen exclusively on the CD34(+)CD117(+) pop-
ulation suggested that NK cells are derived from this popula-
tion and that CD34(+)CD117(−) cells may be functionally 
distinct as it pertains to NK cell developmental potential (Fig. 
1 C). Within the CD34(−) mononuclear fraction of human 
SLT, CD117 expression is absent on CD3(+) T cells and 
CD19(+) B cells, whereas CD34(−)CD117(+) cells display 
a similar gradual up-regulation of CD56 as that seen on 
CD34(+)CD117(+) HPCs and they uniformly coexpress 
the pan-NK cell receptor CD161 (Fig. 1 D). Thus, within 
both CD34(+) and CD34(−) mononuclear fractions of hu-
man SLT, CD117 expression is highly associated with the 
NK cell lineage.
Given these collective data, we hypothesized that human NK 
cells diff  erentiate through four discrete stages within SLT: stage 1, 
CD34(+)CD117(−)CD94(−); stage 2, CD34(+)CD117(+)-
CD94(−); stage 3, CD34(−)CD117(+)CD94(−); and stage 
4, CD34(−)CD117(+/−)CD94(+). Although we did not 
include CD56 as a defi  nitive criterion for the intermediate 
populations, its progressive expression through the stages, 
Figure 1.  Surface marker expression patterns of human SLT popu-
lations. (A) CD3(−)CD56brightCD94(−) cells are absent in BM and PB, yet 
present in human SLT and in NK cell differentiation cultures. All four dot 
plots were gated on CD3(−) events. (B) Distinct patterns of CD34, CD117, 
and CD94 expression within the CD3(−)CD56(+) fraction of human SLT. 
The dot plots were gated on total CD3(−)CD56(+) events. (C) A con-
tinuum of CD56 expression is observed within the CD117(+) fraction of 
SLT CD34(+) HPCs. The left dot plot shows CD34 versus CD45RA expres-
sion within a CD34-enriched preparation from human SLT. The right dot 
plot was gated on CD34(+) events as indicated by the box and arrow in 
the left dot plot. (D) Analysis of CD3, CD19, CD56, and CD161 expression 
on total CD34(−)CD117(+) cells within the mononuclear fraction of hu-
man SLT. The dot plots were gated on CD34(−) SLT preparations. No qual-
itative differences were observed in comparing LN and tonsil specimens. 
The data are representative of at least fi  ve separate analyses.JEM VOL. 203, April 17, 2006  1035
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  including high-density expression within stage 4 being simi-
lar to PB CD56bright NK cells, lends additional support to this 
paradigm of in vivo human NK cell diff  erentiation (Fig. 2). 
Through the remainder of the text, we refer to these four 
populations as stages 1–4.
Surface marker and gene expression profi  les of stages 1–4
To more comprehensively characterize stages 1–4 as they 
  exist in vivo, we fi  rst performed fl  ow cytometric analyses 
on freshly isolated stages as found in SLT, with a focus on 
  antigens expressed by either immature HPCs or mature PB 
NK cells (Fig. 3). In agreement with our model, antigens 
  previously associated with immature lymphoid progenitors, 
  including HLA-DR, CD10, and integrin β7 (9, 18), were 
detected at stages 1 and 2 yet not at stages 3 and 4. In contrast, 
similar to the gradual accumulation of CD56 expression 
within the stages (Fig. 2), CD2, CD7, and CD11b expression 
were gradually increased from stage 1 to 4. Notably, the 
  accumulation of CD11b at stages 3 and 4 is consistent with 
CD11b being a surrogate marker for maturity during in vivo 
mouse NK cell diff  erentiation (8). However, there were no 
detectable diff  erences in terms of CD43 expression in this 
  regard (Fig. 3).
Analysis of NK cell receptors on fresh stages 1–4 found 
within human SLT from multiple donors also revealed a con-
sistent pattern, such that a greater number of these receptors 
was expressed at each progressive stage of diff  erentiation 
(Fig. 3). None of the NK cell receptors we analyzed were 
detected at stage 1. CD161 was consistently the only receptor 
expressed at stage 2, whereas both CD161 and NKp44 were 
detected at stage 3. Stage 4 cells expressed CD161, NKp44 
(albeit at low levels), NKp46, and NKG2D, and we could 
also detect the expression of CD16 and CD158b at stage 4 on 
low percentages of cells, similar to the low level expression of 
CD16 and KIR on PB CD56bright NK cells (15). Similarly, 
surface expression of CD122 was fi  rst noted at stage 3 and 
only readily detectable at stage 4. In contrast to these data, we 
could not detect the expression of NKp30 at any of the four 
stages in SLT (unpublished data).
Next, we compared freshly isolated stages 1–4 for their 
relative messenger RNA (mRNA) expression of genes im-
portant for mouse NK cell development (19). Fig. 4 (A and 
B) shows representative sorts to purify these four populations 
directly from human SLT. As comparisons for the gene 
  expression assay, we also analyzed each transcript in total 
PB CD34(+) HPCs and PB CD56bright NK cells. As a control 
for methodology, CD34 mRNA was highest among PB 
CD34(+) HPCs, lower among stages 1 and 2, and invariably 
undetectable in lysates from stages 3 and 4 and PB CD56bright 
NK cells (Fig. 4 C). Among stages 1–4, CD122 mRNA was 
fi  rst detectable at stage 2, more abundant in stage 3, and rela-
tively more so in stage 4. ETS-1 mRNA is expressed by 
  mature mouse NK cells (20), and we observed that it was 
  detectable at stages 1 and 2, yet higher at stages 3 and 4. Mice 
lacking  GATA-3 and T-BET display NK cell functional 
  defects (21, 22), and it has been postulated that GATA-3 may 
function upstream of T-BET during mouse NK cell diff  eren-
tiation (19). Consistent with this hypothesis, we observed 
that GATA-3 mRNA expression peaked at stage 3, whereas 
T-BET mRNA was low or undetectable at stages 1–3, 
yet relatively much higher at stage 4, comparable to PB 
CD56bright NK cells (Fig. 4 C).
Natural killing and cytokine production of NK cell 
development stages
According to the model of mouse NK cell diff  erentiation 
proposed by Kim et al. (8), acquisition of the capacities to 
mediate natural cytotoxicity and produce cytokines occurs at 
a late stage of maturation in vivo. Limiting cell numbers pre-
vented us from directly assessing such functional capacities of 
stages 1 and 2 from human SLT. However, we were able to 
purify enough fresh stage 3 and 4 cells for analyses. As de-
tected by intracellular fl  ow cytometry, stages 1–3 lack perfo-
rin whereas perforin expression was detected at stage 4 (Fig. 
5 A and not depicted). Accordingly, stage 3 cells showed no 
killing against either K562 or Jurkat target cells, whereas stage 
4 cells displayed >30% and >90% specifi  c lysis against these 
targets, respectively (E/T ratio = 20:1; Fig. 5 B). In the 
  presence of EGTA and MgCl2, the combination of which 
inhibits perforin-mediated killing (13), an anti-TNF–related 
apoptosis-inducing ligand (TRAIL) blocking mAb had no 
eff  ect on the ability of stage 4 cells to lyse Jurkat targets, 
whereas an anti-Fas ligand (FasL) blocking mAb did inhibit 
killing (Fig. 5 C). Therefore, under the conditions tested, 
freshly isolated stage 4 cells mediated both perforin- and 
FasL-dependent killing but not TRAIL-dependent killing, 
similar to PB NK cells (13), whereas stage 3 cells did not me-
diate natural cytotoxicity via any of the three mechanisms.
Freshly purifi  ed stage 3 and 4 cells were also stimulated 
for 12 h in either the combination of IL-12, IL-15, and 
IL-18 or PMA, ionomycin, and IL-2 to assess for cytokine 
Figure 2.  Progressive CD56 expression by in vivo stages of human 
NK cell differentiation. The data were obtained by fi  rst separating 
CD3(−)CD19(−)CD34(+) and CD3(−)CD19(−)CD34(−) fractions from 
SLT mononuclear cell suspensions via magnetic selection and then 
  assessing for CD34, CD117, CD94, and CD56 expression by fl  ow cytometry. 
It was confi  rmed that residual T cells or B cells did not contribute to 
the data.1036  STAGES OF HUMAN NK CELL DIFFERENTIATION IN VIVO | Freud et al.
  production ex vivo (Fig. 5 D). As predicted by the signifi  cant 
diff  erence in T-BET mRNA expression (Fig. 4 C), stage 4 
cells produced IFN-γ under both conditions, whereas IFN-γ 
was not detected in the supernatants of stimulated stage 
3 cells (Fig. 5 D). Similar results were obtained using intracel-
lular fl  ow cytometry to detect IFN-γ, and we were also 
Figure 3.  Surface marker expression profi  les of stages 1–4. 
Data were obtained by performing fl  ow cytomtric analyses of 
CD3(−)CD19(−)CD34(+) and CD3(−)CD19(−)CD34(−) cell preparations 
as in Fig. 2. Shaded regions represent staining for the indicated surface 
antigens, whereas solid lines (open regions) represent staining with appro-
priate isotype-matched control mAbs. The data shown are representative 
of at least three separate experiments for each antigen, and we did not 
  observe any differences in comparing LN and tonsil specimens.
Figure 4.  Gene expression profi  les of stages 1–4. (A and B) Repre-
sentative sorts to purify stages 1–4 from human SLT. Stages 1 and 2 (A) 
and stages 3 and 4 (B) were sorted from CD3(−)CD19(−)CD34(+) and 
CD3(−)CD19(−)CD34(−) fresh SLT cell preparations, respectively, ob-
tained via magnetic selection as described in Materials and methods. 
Additional fl  ow cytometric analyses confi  rmed that sorted stage 3 and 4 
cells were CD34(−) (not depicted). (C) Gene expression analysis of stages 
1–4. Gene expression for each sample was normalized to 18S expression. 
Depending on the preferential expression of each gene of interest, the 
mean of normalized values from either total PB CD34(+) HPCs or total PB 
CD56bright NK cells was set to a value of 1, and all other normalized values 
were adjusted to scale. The y axis of each graph is in arbitrary units and 
measures the adjusted value for each population. The data are expressed 
as the mean of adjusted values ± SD of 3–5 separate samples tested per 
cell population (n = 3–5). CD34, PB CD34(+) HPCs; CD56b, PB CD56bright 
NK cells; S1, stage 1; S2, stage 2; S3, stage 3; S4, stage 4.JEM VOL. 203, April 17, 2006  1037
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  unable to detect IFN-γ production by stages 1 and 2 via this 
method (unpublished data). GM-CSF was detected from 
both stage 3 and 4 supernatants, although stage 3 cells 
  produced less GM-CSF than stage 4 cells and did so only in 
the presence of PMA, ionomycin, and IL-2 (Fig. 5 D). In 
contrast, we could not detect the production of either 
IL-13 or TNF-α after 12-h stimulation of either SLT popu-
lation (unpublished data). Collectively, these data suggest 
that functional maturity occurs within stage 4 of NK cell 
  diff  erentiation in vivo.
Lineage differentiation potentials of stages 1–4
For functional assessment of the lineage potentials of stages 
1–4, we used a series of in vitro diff  erentiation assays. Stages 
1–4 were fi  rst cultured in semi-solid methylcellulose medium 
containing KL, GM-CSF, IL-3, and erythropoietin. Whereas 
multiple CFUs of both erythroid and myeloid lineages were 
derived from a positive control of total PB CD34(+) HPCs, 
we did not observe any CFUs from stages 1–4 in three sepa-
rate experiments (unpublished data). Similarly, we observed 
that in conditions promoting B cell diff  erentiation on MS-5 
stroma using control cord blood (CB) CD34(+)CD19(−) 
HPCs, freshly isolated stages 1–4 failed to give rise to any 
CD10(+)CD19(+) B lineage cells (Fig. 6 A).
Numerous studies indicate that NK cells are develop-
mentally most closely related to T cells and DCs (18, 23–26). 
We cultured stages 1–4 in FL and IL-7 on the OP9-DL1 cell 
line, which supports human T cell diff  erentiation (27). After 
4–5 wk, stage 1 cells underwent profound expansions, with 
cell numbers increasing 1.5 × 102–5.4 × 103-fold (Fig. 6 B). 
In contrast, stages 2–4 displayed less than one tenth the pro-
pensity for proliferation on the OP9-DL1 line. By fl  ow 
  cytometry, both stage 1 and 2 cultures contained CD3(+) 
T cells, which expressed either TCRαβ or TCRγδ recep-
tors, as well as CD3(−)CD4(+/−)CD8(+/−) immature 
T cells (Fig. 6 B and not depicted). However, comparison of 
the absolute numbers of CD3(+) T cells derived from stage 1 
(1.37 × 105 per 103 initiating cells) versus stage 2 (5.7 × 103 
per 103 initiating cells) cells revealed that there was, on aver-
age, a 24-fold diff  erence (P = 0.024). In contrast to these 
  results, we did not observe the generation of CD3(+) T cells 
or CD3(−)CD4(+/−)CD8(+/−) immature T cells in 
  human T cell diff  erentiation cultures initiated with purifi  ed 
stage 3 or 4 cells (Fig. 6 B and not depicted). We did observe 
CD3(−)CD56brightCD94(+) NK cells (stage 4) in these cul-
tures when initiated with freshly isolated stage 1, 2, and 3 
cells (Fig. 6 C), confi  rming that each of these populations is 
capable of giving rise to stage 4 NK cells.
To assess for DC diff  erentiation, purifi  ed stages 1–4 were 
cultured in FL, KL, IL-3, IL-4, GM-CSF, and TNF-α. After 
2 wk, cultures initiated with stages 1–3 maintained live cells, 
although there was an overall net loss in total viable cell num-
ber (mean of 0.14-, 0.35-, and 0.28-fold contractions for 
stage 1–3 populations, respectively). In contrast, stage 4 cells 
all died in these conditions. Cultured cells were harvested for 
analysis by fl  ow cytometry. By forward scatter (FSC) versus 
side scatter (SSC) analysis, stage 1 and 2 cultures contained 
a distinct population that was absent from stage 3 and 4 
cultures. Cells grown out from stage 1 and 2 cultures 
displayed a phenotype consistent with in vitro–derived 
DCs (HLA-DR(+)CD14(−)CD1a(+/−)) and expressed 
co-stimulatory molecules (Fig. 7, A and B; references 18, 25). 
Further, these cells displayed typical DC morphology (Fig. 
7 C). In contrast, stage 3 cultures contained only smaller cells 
that did not display the phenotype shown in Fig. 7 B nor the 
typical DC morphology (unpublished data). Altogether, these 
results suggest that full commitment to the NK cell lineage 
may occur at stage 3 of development in vivo.
Ex vivo NK cell developmental progression of stages 1–4
In addition to the phenotypic and functional assays  performed 
on freshly isolated stages 1–4 of NK cell diff  erentiation, we 
cultured these cells ex vivo to evaluate the eff  ects of individ-
ual cytokines that have been previously shown to support 
NK cell diff  erentiation in vitro (3, 11, 28) and to assess each 
stage for evidence of lineage progression versus reversibility. 
Stages 1 and 2 were fi  rst purifi  ed from human SLT and 
  cultured in IL-15 without any other cytokines or stroma.
Figure 5.  Functional analyses of stages 3 and 4. (A) Perforin expres-
sion of freshly isolated stage 3 and 4 cells as detected by intracellular 
fl  ow cytometry. Shaded regions represent staining with the anti-perforin 
mAb whereas solid lines (open regions) represent staining with the 
  isotype-matched control mAb. Histograms were gated on unsorted 
CD3(−)CD19(−) preparations from human SLT using mAbs directed 
against CD34, CD117, and CD94 to identify discrete stages for analysis. 
Stages 1 and 2 lack detectable intracellular perforin staining (not de-
picted). (B) Percentages of specifi  c lysis against K562 (black bars) and 
Jurkat (gray bars) targets by freshly isolated stage 3 and 4 cells. Data 
shown are the mean results ± SD of four separate experiments per-
formed in triplicate at a 20:1 E/T ratio. (C) Stage 4 cells mediate FasL-
dependent, but not TRAIL-dependent, killing of Jurkat target cells. Data 
shown are the mean results ± SD of triplicate wells from one experiment 
with freshly isolated stage 4 cells targeted against the Jurkat cell line as 
in B but in the presence of 1 mM EGTA and 2 mM MgCl2 (20:1 E/T ratio). 
(D) Production of IFN-γ (left) and GM-CSF (right) by stage 3 and 4 cells 
after 12-h stimulation with either the combination of IL-12, IL-15, and 
IL-18 (black bars) or the combination of PMA, ionomycin, and IL-2 (gray 
bars). Data shown are the combined results ± SD of four separate experi-
ments (n = 4 for each).1038  STAGES OF HUMAN NK CELL DIFFERENTIATION IN VIVO | Freud et al.
As predicted from the CD122 mRNA expression data (Fig. 
4 C), after 2 wk nearly all stage 1 cells died with an overall 
0.17  ± 0.21-fold decrease in total viable cell number, 
whereas cultures initiated with stage 2 cells expanded 
20.1 ± 9.9-fold (P = 0.0001; Fig. 8 A). These data suggest 
that the ability to respond to IL-15 occurs at stage 2 of diff  er-
entiation in vivo. Stage 2 cells cultured in IL-15 primarily 
  became CD3(−)CD34(−)CD56brightCD161(+) and displayed 
a pattern of CD117 versus CD94 expression similar to that 
of total SLT CD3(−)CD56(+) cells in vivo (Fig. 1 B), 
  indicative of progression to stages 3 and 4 (Fig. 8 B and 
not depicted).
Next, we cultured stage 1 cells in IL-15 on MS-5 stroma 
with FL, IL-3, and IL-7 added at the initiation of culture to 
determine if these additional factors would promote NK cell 
diff  erentiation from stage 1. In bulk culture, we observed 
profound expansions (37.1 ± 26.9-fold) compared with cul-
tures in IL-15 alone (n = 4, P = 0.004), and by fl  ow cytom-
etry the cells became CD56brightCD94(+/−) NK cells 
(unpublished data). By limiting dilution analysis on MS-5 
stroma, stage 1 cells cultured in IL-15 plus FL, IL-3, and IL-7 
added at the beginning of culture displayed an increased NKP 
frequency (1/14–1/9) compared with cultures in IL-15 alone 
(1/44–1/37), whereas stage 2 cells displayed a high NKP fre-
quency in IL-15 with or without the additional cytokines 
(<1/3.5) (Fig. 8 C). Thus, stage 1 cells require additional cy-
tokines for diff  erentiation into CD56bright NK cells ex vivo, 
consistent with the notion that stage 1 cells are less mature 
than stage 2 cells that can respond to IL-15.
To gain evidence for a progenitor–progeny relationship 
between stages 1 and 2, respectively, purifi  ed cells were cul-
tured in FL, IL-3, IL-7, and IL-15, and then assessed by 
fl  ow cytometry after 4 d. Reproducibly, we observed the 
appearance of CD34(+)CD117(+) cells in stage 1 cultures, 
whereas CD34(+)CD117(−) stage 1 cells were not de-
tected in stage 2 cultures (Fig. 8 D). Furthermore, cultured 
stage 2 cells displayed lowered CD34 expression than the 
CD34(+)CD117(+) cells that had been derived from stage 
1, suggesting that stage 2 cells were progressing to stage 3 and 
that the appearance of CD34(+)CD117(+) cells in stage 1 
cultures was a result of the de novo generation of these cells 
rather than contamination by stage 2 cells at day 0. As pre-
dicted, after 10 more days of culture in IL-15, we observed 
the exclusive appearance of CD34(−)CD117(+)CD94(−) 
stage 3 and CD34(−)CD117(+/−)CD94(+) stage 4 NK 
cells in cultures initiated with either stage 1 or 2 cells 
  (unpublished data). Thus, under these conditions in vitro, 
freshly isolated stage 1 cells gave rise to stages 2–4, whereas 
freshly isolated stage 2 cells gave rise to stages 3 and 4 but 
not stage 1.
Figure 6.  B and T cell differentiation potential of stages 1–4. 
(A) Representative analysis from one of two experiments culturing SLT-
derived stages 1–4 or CB-derived CD34(+)CD19(−) cells on MS-5 stroma 
in FL, KL, and G-CSF for 6 wk. Dot plots were gated on live cells using a 
lymphocyte gate by FSC versus SSC. (B) Representative analysis from one of 
three experiments in which stages 1–4 were co-cultured for 4–5 wk on the 
OP9-DL1 cell line in FL and IL-7. The OP9-DL1 line expresses GFP. The four 
dot plots shown were gated on GFP(−) events within the live fraction by 
FSC versus SSC analysis. The graph on the right shows the fold increase in 
total GFP(−) cell number starting with 103 cells from each stage (S1–S4). 
n = 1 (representative graph from one of three experiments). (C) Generation 
of CD3(−)CD56brightCD94(+) stage 4 cells on OP9-DL1 stroma. Stage 1–4 cells 
were cultured as in B. The dot plots shown were gated on GFP(−)CD3(−) 
live cell events and are representative of three separate experiments.JEM VOL. 203, April 17, 2006  1039
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Although the results from the OP9-DL1 co-culture ex-
periments demonstrated that freshly isolated stage 3 cells gave 
rise to stage 4 cells ex vivo, those experiments were per-
formed in the absence of exogenous IL-15 (Fig. 6 C). There-
fore, we cultured freshly isolated stage 3 and stage 4 cells for 
2 wk in IL-15 to determine if this cytokine was suffi   cient 
to promote stage 3 to stage 4 diff  erentiation ex vivo (Fig. 9).
Both populations proliferated indicating their responsive-
ness to this cytokine (Fig. 9 A). However, although neither 
population up-regulated CD34, we repeatedly observed that 
only a small fraction (≤2%) of the sorted stage 3 cells were 
induced to express CD94 (stage 4), whereas fresh stage 4 cells 
maintained their phenotype, as predicted by our previous re-
sults culturing PB CD56bright NK cells in IL-15 (Fig. 9 B; 
reference 9). Therefore, additional factors might be necessary 
to drive stage 3 to 4 diff  erentiation in vivo. We previously 
observed that co-culture of total SLT CD34(+) HPCs with 
autologous activated SLT T cells preferentially promoted 
the diff  erentiation of CD56bright NK cells that express CD94 
(unpublished data), suggesting that endogenous factors pro-
duced by activated SLT T cells would promote stage 3 to 4 
NK cell diff  erentiation in vitro. Indeed, in the presence of 
autologous activated SLT T cells, we observed the de novo 
generation of CD3(−)CD34(−)CD117(+/−)CD94(+) 
stage 4 cells in cultures initiated with purifi  ed stage 3 cells, 
whereas CD3(−)CD34(−)CD117(+)CD94(−) stage 3 cells 
were not observed in cultures initiated with purifi  ed stage 4 
cells (Fig. 9 B).
DISCUSSION
The in vivo developmental pathways for human B and T 
lymphocytes have been generally understood for decades, 
and this has been important for studying disease processes 
such as HIV, childhood and adult leukemia, and lymphoma. 
Although in vivo stages of mouse NK cell diff  erentiation 
were recently described (8), the similar populations in hu-
mans have not yet been reported (1, 2). In this study, we 
identifi  ed four novel populations that appeared to represent 
discrete stages of a human NK cell developmental continuum 
within SLT. Each population was isolated directly from these 
tissues and was shown to be capable of downstream NK cell 
diff  erentiation ex vivo (i.e., stage 1 → stage 2 → stage 3 → 
stage 4). Further, we demonstrated that each freshly isolated 
population could be characterized by unique functional and 
phenotypic attributes and that overall progression through 
the stages was characterized by the gradual restriction of 
non-NK cell lineage diff  erentiation potential, concomitant 
with the gradual acquisition of the mature CD56bright NK cell 
phenotype, cytokine production, and mediation of natural 
cytotoxicity. Collectively, these data provide evidence for a 
new model of in vivo human NK cell diff  erentiation.
Many of our results are consistent with previously pub-
lished mouse and human data on this subject (1, 2, 19, 23, 26). 
Specifi  cally, we observed that (a) human NK cells share a 
common developmental origin with T cells and DCs; (b) 
commitment to the NK cell lineage precedes acquisition of 
the capacities for IFN-γ production and natural cytotoxic-
ity; (c) the proposed progression of NK cell development 
in vivo is supported by the observed patterns of CD122, 
ETS-1,  GATA-3, and T-BET mRNA expression; and 
(d) the expression and accumulation of NK cell recep-
tors is nonrandom during in vivo maturation. In addition, 
we observed that CD94 expression in vivo correlates with 
the ability to produce IFN-γ, which is consistent with 
Figure 7.  DC differentiation potential of stages 1–4. 
(A and B) Representative fl  ow cytometric analysis from one of three ex-
periments culturing stages 1–4 in FL, KL, IL-3, IL-4, GM-CSF, and TNF-α. 
(A) By FSC versus SSC analysis, only stage 1 and 2 cultures contained the 
population (black circles) notably absent in stage 3 and 4 cultures. 
(B) Shaded regions in the histograms represent staining for the indicated 
surface antigens whereas solid lines (open regions) represent staining 
with isotype-matched control mAbs. The histograms were gated on the 
populations circled in A from stage 1 and 2 cultures. We did not observe 
any qualitative differences between stage 1– and stage 2–derived DCs. 
(C) Wright/Giemsa staining of stage 1– and stage 2–derived DCs. Note the 
typical DC morphology, including multiple dendrite processes and the 
large nucleus displaced to one side of the cell. Viable cells in stage 3 cul-
tures did not display the DC morphology (not depicted).1040  STAGES OF HUMAN NK CELL DIFFERENTIATION IN VIVO | Freud et al.
previous reports of in vitro human NK cell diff  erentiation 
(12). However, we did observe some functional and phe-
notypic diff  erences between human NK cell intermediates 
derived in vitro and those purifi  ed directly from human SLT. 
For example, CD3(−)CD56brightCD94(−) NK cells derived 
in vitro uniformly express NKp44 and NKp46 (9, 14), yet 
these expression patterns were not observed in vivo. Further-
more, whereas CD94(−) immature NK cells derived in vi-
tro can mediate TRAIL-dependent killing and produce large 
amounts of IL-13 (12, 13), we did not detect these functions 
from stage 3 intermediates isolated ex vivo. The reasons for 
these diff  erences are not yet known. However, considering 
that in vivo diff  erentiation to a stage 4 cell is associated with 
the acquisition of the capacities for both natural killing and 
IFN-γ production, this process is likely to be tightly regu-
lated to ensure self-tolerance and, therefore, may not be fully 
recapitulated in culture systems currently used to study hu-
man NK cell diff  erentiation. In addition, we currently do not 
know the specifi  c mechanisms of action of many cytokines, 
including FL, IL-3, IL-7, and IL-15, that have been previ-
ously implicated as critical in this pathway (3, 11, 28), nor 
do we yet know whether the cytokines themselves are pres-
ent in SLT near developing NK cells at the concentrations 
used to promote NK cell diff  erentiation in vitro. Therefore, 
these discrepancies may result from missing factors and/or 
the   addition of nonphysiological stimuli during NK cell 
  development in vitro.
In light of the aforementioned data, it is also noteworthy 
that IL-15 stimulation alone was insuffi   cient to promote sub-
stantial stage 4 diff  erentiation from freshly isolated stage 3 cells 
despite the generation of stage 4 cells in IL-15–supplemented 
stage 1 and 2 cultures as well as in cultures initiated with BM 
or PB CD34(+) HPCs (9). One interpretation of these data is 
that IL-15 may have induced the diff  erentiation of stage 4 
cells directly from stage 2, thus bypassing stage 3. However, 
this is not supported by the fact that CD34 and CD94 are 
mutually exclusive antigens, both in vitro and in vivo, and we 
would expect to fi  nd some CD34(+)CD94(+) intermediates 
in human SLT if this was the case. Stage 3 cells in vivo display 
a phenotype that is intermediate between those of stage 2 and 
4 cells in terms of CD2, CD7, CD11b, CD56, CD117, 
CD161, and NKp44 expression. Furthermore, freshly isolated 
stage 3 cells failed to generate T cells or DCs, yet reproducibly 
gave rise to stage 4 cells when cultured with either activated 
Figure 8.  Stage 1 and 2 NK cell developmental progression. 
(A) Sorted stage 1 and 2 cells were cultured in IL-15 for 2 wk and then total 
viable cell counts were determined. Cultures were initiated with 103 starting 
cells. Shown are the mean results from seven separate experiments ± SD. 
n = 7. (B) Representative phenotypic analysis of stage 2 cells cultured in 
IL-15 for 2 wk. The few viable cells remaining in stage 1 cultures after 2 wk 
in IL-15 displayed a similar phenotype shown for cultured stage 2 cells. 
(C) Limiting dilution analysis of stages 1 and 2 cultured in either IL-15 
alone (○) or IL-15 with the one time addition of FL, IL-3, and IL-7 at the 
initiation of culture (■). The graphs show initiating stage 1 and 2 cell 
numbers versus the percentages of NK-positive wells for one of two 
  separate experiments yielding similar results. (D) De novo generation of 
CD34(+)CD117(+) cells from purifi  ed stage 1 cells. Purifi  ed stage 1 and 2 
cells were cultured for 4 d in FL, IL-3, IL-7, and IL-15 and then analyzed by 
fl  ow cytometry for the expression CD34 and CD117. Unsorted, unstained 
CD34-enriched cell preparations (obtained via magnetic selection) were 
cultured in parallel to set voltages and compensation parameters on the 
fl  ow cytometer. Results are representative of three separate experiments.
Figure 9.  Stage 3 to 4 differentiation ex vivo. (A) Proliferation of 
stage 3 and 4 cells cultured in IL-15. Shown are the mean results ± SD 
from seven separate experiments starting with 103 cells. n = 7. (B) Repre-
sentative phenotypic analysis of one of three experiments with stage 3 
and 4 cells cultured either in IL-15 (left dot plot for each population) or 
in IL-15 plus activated autologous SLT T cells (right dot plot for each 
population). All four dot plots were gated on total CD3(−) events, and 
none of the cultured cells expressed CD34 (not depicted). Cultures initi-
ated with activated SLT T cells alone did not contain CD3(−)CD94(+) 
cells (reference 9).JEM VOL. 203, April 17, 2006  1041
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SLT T cells or OP9-DL1 stroma. Therefore, we favor the 
hypothesis that stage 4 cells are the direct progeny of stage 3 
cells in vivo and that this diff  erentiation step may require sig-
nals other than, or in addition to, IL-15. Moreover, we spec-
ulate that signals promoting stage 4 diff  erentiation may be 
common to OP9-DL1 and activated SLT T cell co-cultures 
as well as to cultures initiated with CD34(+) HPCs.
The work presented here provides new evidence that 
LNs and tonsils are sites for human NK cell development in 
vivo. Previous studies established that CD56bright NK cells 
predominate in SLT (16, 17), and we have now demonstrated 
that these tissues are also naturally and selectively enriched 
with the full complement of newly discovered intermediates 
spanning the continuum of NK cell diff  erentiation from a 
CD34dimCD45RA(+) progenitor to a mature CD56bright NK 
cell. However, there are now many new questions that arise 
from this study. For example, it is still unclear how SLT-
  derived NK cells might be related to NK cells in other 
  compartments in the body. Although SLT stage 4 cells closely 
resemble PB CD56bright NK cells in terms of their phenotypic 
and functional attributes, it is possible that SLT-resident NK 
cells represent a lineage distinct from that of CD56bright NK 
cells in the blood, as has been postulated for human decidual 
NK cells (29). In addition, the majority of NK cells in PB are 
CD56dim and express high levels of CD16 and KIRs (15). 
Based on their phenotypic and functional characteristics, we 
speculate that PB CD56dim NK cells might represent the ter-
minally diff  erentiated stage of human NK cell development 
(stage 5). However, we currently lack direct evidence to sup-
port this hypothesis and cannot yet formally exclude the pos-
sibility that PB CD56bright and/or CD56dim NK cells might be 
derived from distinct NKPs that diff  erentiate in the BM.
It is also unclear to what extent stage 4 cells, or any of the 
other NK cell lineage populations, actually arise within SLT 
or merely traffi   c through these tissues. On the one hand, our 
fl  ow cytometry data provide strong evidence for the exis-
tence of ongoing NK cell maturation within these tissues, as 
for example analysis of CD94 versus CD117 expression re-
veals a continuous pattern with cells at all points in the spec-
trum between stages 3 and 4 (Fig. 1 B). On the other hand, 
previous evidence suggests that both PB CD34(+) NKPs and 
PB CD56bright NK cells have the capacity to migrate into 
SLT, given the relatively high expression of l-selectin on 
these subsets in the blood versus low or undetectable expres-
sion within SLT (9, 17, 30). Therefore, some of these cells, 
in particular those that we have characterized as stage 4, may 
have recently migrated into SLT from other sites. In future 
studies it will be important to determine the relative capacity 
for NK cell developmental intermediates to recirculate in and 
out of multiple lymphoid organs, given the potential implica-
tions regarding self-tolerance acquisition and overall regula-
tion of this process in vivo.
A primary goal of this study was to identify surface an-
tigens that could be used to specifi  cally and positively iden-
tify developing human NK cells in vivo, ideally providing an 
all-inclusive framework on which to base future research on 
the NK cell developmental pathway. In this regard, CD34, 
CD117, and CD94 are useful antigens because they are rela-
tively specifi  c to the NK cell lineage in SLT, they provide 
continuity for “following” developing NK cells, and they ac-
count for most if not all of the CD3(−)CD56(+) cells within 
these tissues. However, stages 1–4 as we defi  ned them are 
likely to be functionally heterogeneous, with the potential to 
identify additional subsets within each of these populations. 
For example, our fl  ow cytometric analyses revealed that stage 
1 and 2 cells are heterogeneous with regards to the expression 
of CD2, CD7, CD10, and CD56. Therefore, in future experi-
ments, it might be determined that the true NK cell progeni-
tors within the stage 1 population are distinct from non-NK 
lineage cells that share the CD34(+)CD45RA(+)CD117(−) 
phenotype or that the stage 2 population consists of mono-
committed T, DC, and NKP rather than cells with multi-
potency. Indeed, we cannot rule out these possibilities using 
the techniques we used in our study. In addition, there are 
expected to be diff  erentiation steps that are downstream of 
the acquisition of CD94, including those involving the ac-
quisition of CD16 and KIRs. Therefore, future studies are 
warranted to continue to refi  ne the human NK cell devel-
opmental pathway in vivo and to elucidate the physiological 
mechanisms regulating this process in SLT.
MATERIALS AND METHODS
Cell isolation from human tissues. All protocols were approved by the 
Ohio State University (OSU) Institutional Review Board. The data in this 
study were generated from the combined analyses of tissue specimens from 
>50 tonsil and 30 LN donors and we observed no appreciable diff  erences be-
tween LNs and tonsils by phenotype or functional assays. Normal human ton-
sils and LNs were obtained within 24 h of elective surgery through the Tissue 
Procurement Shared Resource of the OSU Comprehensive Cancer Center 
or from brain dead tissue donors through the National Disease Research 
Interchange (NDRI). Tissue cells were dispersed through 70-μm cell strain-
ers into sterile PBS followed by fi  coll centrifugation. For each donor’s tissues, 
all cells from multiple tonsil pieces or multiple LNs were pooled to obtain 
suffi   cient numbers of NK cell developmental intermediates for the experi-
ments. Mononuclear fractions were depleted of CD3(+) and CD19(+) cells 
via magnetic negative selection (Miltenyi Biotec). For certain experiments, 
T and B cell-depleted preparations were either stimulated to detect intracel-
lular IFN-γ production or directly stained with mAbs for phenotypic analyses. 
Alternatively, CD34(+) cells were enriched from CD3(−)CD19(−) prepara-
tions with the CD34 progenitor isolation kit (Miltenyi Biotech), subsequently 
stained with FITC-conjugated anti-CD45RA, phycoerythrin-conjugated 
anti-CD117, and APC-conjugated anti-CD34 mAbs (BD Biosciences), and 
sorted for stage 1 (CD34(+)CD45RA(+)CD117(−)) and stage 2 (CD34(+)
CD45RA(+)CD117(+)) populations with a FACSVantage cell sorter (BD 
Biosciences). Remaining CD3(−)CD19(−)CD34(−) cells were stained with 
the combination of FITC-conjugated anti-CD94 mAb (clone 131412; R&D 
Systems), phycoerythrin-conjugated anti-CD117, APC-conjugated anti-CD3, 
and APC-conjugated anti-CD34 mAbs (BD Biosciences), and stage 3 (CD3-
(−)CD34(−)CD117(+)CD94(−)) and stage 4 (CD3(−)CD34(−)CD117-
(+/−)CD94(+)) populations were sorted to >99% purity. SLT-derived 
T cells and BM, PB, and CB (obtained from NDRI) mononuclear cell popu-
lations were obtained as previously described (9).
Flow cytometry. All mAbs used in this paper were purchased from BD 
Biosciences, except CD16, CD56, CD122, CD158b, NKp30, NKp44, 
NKp46 (Beckman Coulter), and CD94 (R&D Systems). Flow cytometry 
and data analyses were performed as previously described (9).1042  STAGES OF HUMAN NK CELL DIFFERENTIATION IN VIVO | Freud et al.
Real-time PCR. RNA extraction and reverse transcription from ≥2 × 104
sorted cells were performed as described previously (31). All primers 
and probes were designed using Primer Express software (Applied Biosys-
tems) and the sequences are as follows: CD34: forward 5′-A  T  C  G  C  C  G  C-
A  G  C  T  G  G  A  G  -3′, reverse 5′-C  C  G  T  T  T  T  C  C  G  T  G  T  A  A  T  A  A  G  G  G  T  -3′, 
probe 5′-FAM-C  C  A  C  A  G  G  A  G  A  A  A  G  G  C  T  G  G  G  C  G  A  -Tamra-3′; CD122: 
forward 5′-C  C  T  G  G  C  T  A  C  C  T  C  T  T  G  G  G  C  A  -3′, reverse 5′-G  A  A  G  C  A  T-
G  T  G  A  A  C  T  G  G  G  A  A  G  T  G  -3′, probe 5′-FAM-T  G  C  A  G  C  G  G  T  G  A  A  T  G  -
MGB-3′; ETS-1: forward 5′-C  G  A  T  C  T  G  G  A  G  C  T  T  T  T  C  C  C  C  -3′, reverse 
5′-T  G  G  A  G  T  T  A  A  T  A  G  T  G  G  G  A  C  A  T  C  T  G  C  -3′, probe 5′-FAM-C  C  C  C  G-
G  A  T  A  T  G  G  A  A  T  G  -MGB-3′; GATA-3: forward 5′-A  A  A  T  G  A  A  C  G  G  A  C-
A  G  A  A  C  C  G  G  -3′, reverse 5′-T  G  C  T  C  T  C  C  T  G  G  C  T  G  C  A  G  A  C  -3′, probe 
5′-FAM-C  C  C  T  C  A  T  T  A  A  G  C  C  C  A  A  G  C  G  A  A  G  G  C  -Tamra-3′;  T-BET: 
forward 5′-C  A  A  C  A  A  T  G  T  G  A  C  C  C  A  G  A  T  G  A  T  -3′, reverse 5′-A  A  T  C  T  C-
G  G  C  A  T  T  C  T  G  G  T  A  G  G  -3′, probe 5′-FAM-C  C  G  G  C  T  G  C  A  T  A  T  C  G  T  T-
G  A  G  G  T  G  A  A  C  -Tamra-3′. Real-time PCR reactions were performed in 
a sequence detector (ABI prism 7700; Applied Biosystems) as follows: 50°C 
for 2 min; 95°C for 10 min; and 45 cycles of 95°C for 15 s and 60°C for 
1 min. Data were analyzed with the Sequence Detector version 1.6 software to 
establish the PCR cycle at which fl  uorescence exceeded a set threshold, CT, 
for each sample. Experimental CT values were used to calculate gene-specifi  c 
copy numbers from a standard curve, and the gene-specifi  c copy numbers 
were normalized to ribosomal 18S copy numbers from the same samples.
Cytotoxicity assays and cytokine production. Cytotoxicity assays were 
performed in 100 μl RPMI-1640 medium with GlutaMAX containing 10% 
FBS and antibiotics (Invitrogen) in 96-well V-bottom plates (BD Biosci-
ences) with 2 × 102 K562 or Jurkat cloned targets stably infected with mouse 
stem cell virus retrovirus to express the fi  refl  y luciferase enzyme. After 8-h 
incubations, cell pellets were lysed with passive lysis buff  er (Promega) and 
frozen at −80°C. 25 μl of thawed lysates were transferred into Costar 96-
well fl  at-bottom solid-white plates (Fisher Scientifi  c) and mixed with 100 μl 
of Luciferase assay reagent (Promega) by a Fluoroskan Ascent FL luminome-
ter (Thermo Electron, Inc.). Luminescence was measured as relative light 
units (RLU) during 10-s intervals. The percent of specifi  c lysis for each ex-
periment was calculated as [(mean RLU from wells containing target cells 
only) − (mean RLU from experimental wells)]/(mean RLU from wells 
containing target cells only) × 100%. Blocking experiments with the Jurkat 
cell line were performed with 1 mM EGTA and 2 mM MgCl2. The anti-
TRAIL (clone RIK-2), anti-FasL (clone NOK-2), and isotype-matched 
control mAbs (BD Biosciences) were used at 10 μg/ml.
For cytokine production, 2 × 104 purifi  ed stage 3 or 4 cells were stimu-
lated in either the combination of 10 ng/ml IL-12 (Genetics Institute), 
100 ng/ml IL-15, and 100 ng/ml IL-18 (BASF) or 50 ng/ml PMA (Sigma-
Aldrich), 1 μM ionomycin (Calbiochem), and 1 nM IL-2 (Hoff  man 
  LaRoche) for 12 h at 37°C. Supernatants were analyzed by ELISA for the 
production of IFN-γ as described previously (32) using commercially avail-
able mAbs (Endogen) or for the production of GM-CSF, TNF-α, and IL-13 
using Quantikine ELISA kits (R&D Systems).
Cell culture. Stroma-free cultures were in 96-well round-bottom plates (BD 
Biosciences) in 200 μl RPMI-1640 medium with GlutaMAX (Invitrogen), 
10% heat-inactivated human AB serum (ICN Biomedicals), antibiotics and 
additional supplements previously described (9). Recombinant human IL-15 
was provided by Amgen and used at 1 nM. Human KL (Amgen) and FL (Pe-
protech) were used at 100 ng/ml, whereas human IL-3, IL-4, IL-7, G-CSF, 
GM-CSF, and TNF-α (R&D Systems) were used at 10 ng/ml each. Acti  vated 
T cell co-culture experiments were performed in 200 μl of medium with 104 
freshly isolated SLT stage 3 or 4 cells and 2.5 × 103 autologous SLT CD3(+) 
T cells (purifi  ed via sorting [reference 9]) with 5 × 103 anti-CD3/CD28 
beads (Dynal) and IL-15. Half the medium was replaced every 3–4 d to re-
plenish IL-15 only. Co-cultures on MS-5 stroma (a gift of J.E. Dick,   Toronto 
General Research Institute, Toronto, Canada) were in 96-well fl  at-bottom 
plates (BD Biosciences) in 200 μl α-MEM plus 20% FBS and anti  biotics (all 
from Invitrogen) replacing half the medium every 3–4 d. CFU assays were 
performed with MethoCult GF+ from StemCell Technologies following the 
manufacturer’s protocol. T cell diff  erentiation cultures on the OP9-DL1 cell 
line (provided by J.C. Zúñiga-Pfl   ücker, University of Toronto, Toronto, 
Canada) were maintained in α-MEM plus 20% FBS, antibiotics, FL, and IL-7 
and were performed as described previously (27). Morphologies of in vitro–
derived DCs were assessed via cytospin and Wright/Giemsa staining.
Limiting dilution analysis. Purifi  ed stage 1 and 2 cells were cultured at 
50, 25, 12.5, 6.25, 3.125, and 1.5625 cells per well, 10 replicates each, on 
MS-5 stroma in either IL-15 alone or IL-15 with the one time addition of 
FL, IL-3, and IL-7 at the initiation of culture. Half the medium was changed 
every 3–4 d to replenish IL-15 only. It was confi  rmed that all live human 
cells remaining in such cultures after 3 wk were CD56bright NK cells (unpub-
lished data). Therefore, wells that contained visible growth (compared with 
wells not seeded with HPCs) were scored positive for NK cells, whereas 
wells that did not contain visible growth were harvested, stained with phy-
coerythrin-conjugated anti-CD56 mAb, and assessed by fl  ow cytometry for 
the presence or absence of CD56bright NK cells. NKP frequencies reported in 
the text were calculated as the reciprocal of the concentration of cells that 
resulted in ≥63% positive wells using Poisson statistics and the weighted 
mean method, as described previously (11).
Statistical analyses. Data were log transformed and analyzed using a paired 
Student’s t test to obtain p-values. S-Plus version 6.0 and SAS version 8.02 
software were used for the analyses.
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